Sarepta Therapeutics' (SRPT) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research note published on Tuesday, Benzinga reports. The brokerage currently has a $148.00 price target on the biotechnology company’s stock. Other equities research analysts have also recently issued research reports about the stock. Needham & Company […]

Related Keywords

Canada ,Montreal ,Quebec ,Richard Barry ,Douglass Ingram ,Tekla Capital Management ,Needham Company ,Sarepta Therapeutics Inc ,Royal Bank ,Mirae Asset Global Investments Co ,Jpmorgan Chase Co ,Cantor Fitzgerald ,First Horizon Advisors Inc ,Sarepta Therapeutics ,Free Report ,Moderate Buy ,Get Free Report ,Director Richard Barry ,Asset Global Investments ,Horizon Advisors ,Montreal Can ,Capital Management ,Sarepta Therapeutics Daily ,Nasdaq Srpt ,Srpt ,Medical ,Reiterated Rating ,Royal Bank Of Canada ,